The traditional approaches to chemical risk assessment for human health are continuously challenged by their limitations, such as validity concerns, societal pressure to use animal-free methods, and resource constraints. New Approach Methodologies (NAMs) are considered a promising avenue toward modernisation of chemical risk assessment practices but their implementation in practice has been slow. This article aims to investigate the perspectives of human health risk assessors on the status quo, barriers and drivers of the acceptance and use of NAMs across different regulatory frameworks. A mixed method design was applied: qualitative interviews (N = 19) and an online survey with human health risk assessors from industry, regulatory agencies/institutions and academia (N = 222). The results show heterogeneity in familiarity and use of specific NAMs (e.g., QSARs as well-known and used vs. -omics approaches that are seldom used), the risk assessors' background (e.g., industry vs. regulatory agencies and institutions vs. academia) and the application context (e.g., screening/prioritisation vs. hazard identification/characterisation). The identified barriers and drivers offer pointers for the future integration and acceptance of NAMs in regulatory risk assessment. For instance, guidance documents can facilitate the use of NAMs, showcasing successful examples that increase trust in the methods and thus, the risk assessors' confidence in using these methods. Among other things, the article highlights the importance of considering human health risk assessors' needs and prerequisites to foster bottom-up coordinated efforts and to ensure the success of top-down legal and institutional change to incorporate NAMs in regulatory risk assessment.
• Survey reveals areas of consensus between animal welfare and environmental protection NGOs on utilization of new approach methodologies (NAMs) to assess the risk of chemicals. • Broad consensus was identified for the need of a more precise definition of NAMs by making reference to using NAMs in specific contexts, acknowledging that existing processes are not adequate to validate new approach methodologies and that there remain clear barriers to the regulatory deployment of NAMs. • Understanding these areas of common ground will benefit future policy decision-making related to the acceptance of NAMs in chemical safety assessments.
Import and export controls ensure plant pests and diseases harmful to food production, the plants across our landscape, and ecosystem services, are not moved during trade. The ‘International Plant Protection Convention’ (IPPC) provides the framework for applying preventive measures where they are technically justified, and stipulates controls are not to be used as arbitrary restrictions on international trade. This article examines the aims of the Brexit trade agreements and reviews their alignment with the IPPC and other World Trade Organisation agreements. It argues that unjustified controls have been applied under the guise of protective requirements (contributing to EU-GB trade disruption) and identifies a divergence at the point of regulatory implementation of these laws and treaties by official bodies on both sides. The article reviews the position of Northern Ireland, which, to avoid a ‘hard border’ on the island of Ireland, remains under the European Union (EU)'s plant health (phytosanitary) regime. Reflecting on legislative options available to bring the application of plant health regulations into alignment with the IPPC (such as dispute resolution), these options remain unused. However, the possibility of utilising ‘import authorisations’ would leave neither Great Britain nor EU Member States exposed to any greater environmental risk than that under the single market.
The gradual rate of phasing out animal use in regulatory testing has been attracting greater attention from policy makers, the scientific community, and industry. In this paper we analyse the extent to which the strategic 'Roadmap Towards Phasing Out Animal Testing for Chemical Safety Assessments' of the European Commission is able to address sociotechnical barriers that have thus far hindered the greater regulatory acceptance of NAMs, including: the lack of consensus when applying scientific developments to value-laden risk assessments that have inherent uncertainties; the lack of stakeholder participation; regulatory culture; and routes to assurance. The roadmap is predominantly focused on the technical aspects of the transition, leaving the social nature of barriers to be addressed in greater detail in the implementation phase. A review of legal frameworks underpinning the roadmap identifies that more extensive statutory interpretation, particularly regarding the use of Weight-of-Evidence, would aid regulatory acceptance of NAMs. The paper critiques the short-, mid-, and long-term actions of the roadmap, and notes the absence of consideration of the EU judicial system, which plays an important role in providing interpretation to EU chemical law and its enforcement, in particular the obligation to use animal testing as a last resort. Although setting a clear final intention, this paper notes that with the longer-term goal to replace the use of non-protected life stages and invertebrates, and without hard milestone dates by which to indicate progress, the roadmap as a strategy is only able to provide limited clarity that NAM innovators and investors seek.